Spirulina MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy ApplicationBy End UserBy Distribution ChannelBy Cultivation Method

Spirulina is a blue-green microalgae, principally Arthrospira platensis, cultivated and processed into powder, tablet, capsule, flake and liquid extract forms sold as a protein- and micronutrient-dense ingredient. Buyers include dietary supplement and functional food manufacturers, animal feed and aquaculture formulators, cosmetic and personal care producers, and the retailers and e-commerce platforms that sell finished spirulina products to consumers. The market covers both bulk biomass supplied as a raw ingredient to formulators and finished, consumer-ready products.

Growth of 8.31% a year carries the global spirulina market from USD 690 million in 2025 to USD 1414.2 million in 2034. The full series behind that rate covers USD 428.5 million in 2020, USD 618 million in 2024, USD 747.3 million in 2026 and USD 1028 million in 2030, with 2025 as the base year.

The product type mix shifts over the period. Powder is the largest line in 2025 at USD 376.1 million, a 54.5% share, moving to USD 707.1 million and 50% by 2034. Tablets & Capsules grows fastest at 10.07%, taking its share from 28.5% to 33%, while Flakes grows slowest at 5.97%. The lines gaining share are Tablets & Capsules and Liquid Extract. Powder and Flakes lose share without losing revenue.

Cut by application, the largest line is Nutraceuticals & Dietary Supplements: 48% of 2025 revenue, worth USD 331.2 million, and 45% at USD 636.4 million by 2034. Pharmaceuticals grows faster at 10.52% against 7.52%, moving from 5% of revenue to 6% by 2034. Both this axis and the product type one divide the same revenue, which is why they are alternative views, not components.

The regional order runs from Asia Pacific at 37.4% of 2025 revenue down to Middle East and Africa at 6%. Asia Pacific is worth USD 258.3 million in 2025 and USD 565.7 million in 2034; North America, second at 28.3%, moves from USD 195.2 million to USD 381.8 million. Share shifts toward Asia Pacific over the forecast period, so the regional split repays a close reading.

Behind these figures sit five regions, four product type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 8.31% takes the market from USD 690 million in 2025 to USD 1414.2 million in 2034, against 10% recorded over the 2020-2025 historical period.
• The largest line by product type is Powder, worth USD 376.1 million and 54.5% of revenue in 2025, rising to USD 707.1 million and 50% by 2034.
• Fastest growth on the product type axis belongs to Tablets & Capsules: 10.07% a year, USD 196.7 million to USD 466.7 million, and a share moving from 28.5% to 33%.
• Scenario range for 2034 runs from USD 1165.8 million in the bear case to USD 1627 million in the bull case, against a base-case USD 1414.2 million, the spread a plan built on this forecast has to absorb.
• 37.4% of 2025 revenue is generated in Asia Pacific, worth USD 258.3 million and rising to USD 565.7 million by 2034; Middle East and Africa is smallest at 6%.
• China accounts for 42% of Asia Pacific in the base year, worth USD 108.5 million in 2025 and reaching USD 237.6 million by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three movements define the forecast period in the global spirulina market: how the product type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Composition shifts on the product type axis. Between 2026 and 2034, 10.07% growth in Tablets & Capsules against 5.97% in Flakes pulls the product type mix apart. Shares follow: 28.5% to 33% for Tablets & Capsules, 7.3% to 6% for Flakes. In absolute terms Tablets & Capsules rises from USD 196.7 million to USD 466.7 million, while Flakes rises from USD 50.3 million to USD 84.9 million. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

The regional balance moves. Asia Pacific moves from 37.4% of revenue in 2025 to 40% in 2034, worth USD 258.3 million rising to USD 565.7 million. The remaining regions grow in absolute terms while giving up share: North America at 28.3% moving to 27%, Europe at 20.3% moving to 19%, Latin America at 8% moving to 8%, Middle East and Africa at 6% moving to 6%. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

The series never breaks trajectory. Reading the series: USD 428.5 million in 2020, USD 618 million in 2024, USD 690 million in 2025, USD 747.3 million in 2026, USD 1028 million in 2030 and USD 1414.2 million in 2034. There is no discontinuity to time, and 8.31% forecast growth against 10% historical means the trend continues and does not turn. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the product type and regional mixes matter more to a forecast than the headline rate does.

Tablets & Capsules adds the most incremental growth

Three sources account for the growth to 2034: 8.31% compounding across the base, share moving toward the faster product type lines, and above-market expansion in the leading regions.

What holds the forecast back

What the bull case turns on

Revenue is concentrated in Powder

In North America, 28.3% of global revenue puts 2025 at USD 195.2 million with USD 381.8 million projected for 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Its share moves to 27% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The product type mix reported at global level applies here, with Powder the largest line at 54.5% of 2025 revenue and Tablets & Capsules the fastest-growing at 10.07%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 165.9 million in 2025 and projected to reach USD 324.5 million by 2034. At 85% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 195.2 million and USD 381.8 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Powder at 54.5% of 2025 revenue, easing to 50% by 2034, and the fastest is Tablets & Capsules at 10.07%, from 28.5% to 33%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by product type for the United States is reported separately in the full report.

In the United States, spirulina intended for human consumption is regulated by the Food and Drug Administration primarily as a dietary ingredient under the framework established by the Dietary Supplement Health and Education Act. A supplier bringing a spirulina supplement to market does not need premarket approval from the agency but must ensure the product is neither adulterated nor misbranded, carries a Supplement Facts panel rather than a Nutrition Facts panel, and avoids disease-treatment claims that would reclassify it as an unapproved drug. Spirulina extract used as a food colorant has separately been reviewed by the FDA as a color additive, and any use in that capacity must conform to the specific conditions set out for that approval. The Federal Trade Commission oversees advertising claims made about the product's health benefits.

The United States does not have a competitive structure of its own; position here is position on the product type axis reported above. Two different problems sit on the same axis: holding Powder at 54.5% of 2025 revenue, and taking Tablets & Capsules while it grows at 10.07%. Country-level shares and positioning per company sit in the full report.

4.2% of global revenue is generated in Canada; USD 29.3 million in 2025, reaching USD 57.3 million in 2034, and 15% of North America.

USD 140 million of 2025 revenue is generated in Europe, 20.3% of the global spirulina market with USD 268.7 million projected for 2034. It is a leading region on this axis, third by revenue throughout the period.

Its share moves to 19% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Powder leads here as it does globally, at 54.5% of 2025 revenue, and Tablets & Capsules again grows fastest at 10.07%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

Germany is the largest market within Europe, generating USD 42 million in 2025 and projected to reach USD 80.6 million by 2034. 30% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 140 million in 2025 and USD 268.7 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Germany follows the product type mix reported at global level: Powder is the largest line at 54.5% of 2025 revenue, moving to 50% by 2034, while Tablets & Capsules grows fastest at 10.07% and takes its share from 28.5% to 33%. With 30% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Germany carries its own product type breakdown in the full report.

In Germany, spirulina sold as a food or food supplement falls under European Union food law as implemented by national authorities, with the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit responsible for enforcement alongside regional food safety offices. Because spirulina in certain concentrated or extracted forms can fall within the scope of the EU Novel Food Regulation, a supplier must confirm whether its specific preparation requires novel food authorisation before sale, or whether it qualifies as a traditional food ingredient exempt from that route. Supplements containing spirulina must comply with the EU Food Supplements Directive and the Food Information to Consumers Regulation, covering permitted health claims, allergen disclosure, and nutrient labelling. Any cosmetic application is governed instead by the EU Cosmetics Regulation.

Competition in Germany is decided on the product type axis rather than on geography, since suppliers here sell into the same product type lines reported globally. Two different problems sit on the same axis: holding Powder at 54.5% of 2025 revenue, and taking Tablets & Capsules while it grows at 10.07%. That makes Europe a 20.3% share of 2025 global revenue, USD 140 million rising to USD 268.7 million, for any supplier deciding where to concentrate.

France is sized at USD 30.8 million in 2025, rising to USD 59.1 million by 2034; 4.5% of global revenue and 22% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 37.4% of global revenue puts 2025 at USD 258.3 million rising to USD 565.7 million in 2034. Among the five regions it ranks first by revenue in both years.

Its share rises to 40% over the forecast period, on growth above the market's own 8.31%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The product type mix reported at global level applies here, with Powder the largest line at 54.5% of 2025 revenue and Tablets & Capsules the fastest-growing at 10.07%. Per-axis and per-country detail for Asia Pacific sits in the full report.

USD 108.5 million of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 237.6 million by 2034. 42% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 258.3 million to USD 565.7 million over the same period, and this is the market carrying the country-level detail in the full report.

Demand in China follows the product type mix reported at global level: Powder is the largest line at 54.5% of 2025 revenue, moving to 50% by 2034, while Tablets & Capsules grows fastest at 10.07% and takes its share from 28.5% to 33%. Since 42% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for China appears on its own in the full report.

In China, spirulina used as an ordinary food ingredient is regulated under the national food safety standards system overseen by the State Administration for Market Regulation, which sets composition, hygiene, and labelling requirements a supplier must meet before sale. Where a spirulina product is marketed with specific health function claims, it falls instead under the Health Food registration and filing system administered by the National Medical Products Administration, commonly known by its Blue Hat designation, requiring the manufacturer to substantiate the claimed function and obtain the corresponding approval before the product reaches shelves. Packaging must disclose ingredients and any permitted health claim in the form the regulator has approved, and imported spirulina products are subject to customs inspection against the same standards applied domestically.

Competition in China is decided on the product type axis rather than on geography, since suppliers here sell into the same product type lines reported globally. Two different problems sit on the same axis: holding Powder at 54.5% of 2025 revenue, and taking Tablets & Capsules while it grows at 10.07%. Weighting toward Asia Pacific means competing for 37.4% of 2025 global revenue, a base of USD 258.3 million moving to USD 565.7 million across the forecast period.

9.4% of global revenue is generated in India; USD 64.6 million in 2025, reaching USD 141.4 million in 2034, and 25% of Asia Pacific.

Japan is sized at USD 38.7 million in 2025, rising to USD 84.9 million by 2034; 5.6% of global revenue and 15% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

8% of the global spirulina market sits in Latin America in 2025, worth USD 55.2 million rising to USD 113.1 million in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

Share settles at 8% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Powder the largest line at 54.5% of 2025 revenue and Tablets & Capsules the fastest-growing at 10.07%. Latin America is reported axis by axis and country by country in the full study.

The largest single market in Latin America is Brazil, at USD 30.4 million in 2025 and USD 62.2 million in 2034. It accounts for 55% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 55.2 million in 2025 and USD 113.1 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The product type pattern in Brazil is the global one: 54.5% of 2025 revenue in Powder, 50% by 2034, against 10.07% growth in Tablets & Capsules taking it from 28.5% to 33%. Its 55% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by product type separately.

In Brazil, spirulina marketed as a food supplement is regulated by the Agência Nacional de Vigilância Sanitária, which classifies such products under its framework for food supplements, distinct from conventional foods and from medicines. A supplier must notify or register the product with the agency depending on its formulation, ensure the composition conforms to the permitted substances and dosage forms set out for supplements, and label the product clearly as a food supplement without implying a therapeutic effect. ANVISA's labelling rules require disclosure of composition, recommended intake, and warnings against exceeding that intake, and any function claim must fall within the categories the agency has already reviewed and permitted.

Supplier positions in Brazil sit on the product type axis: the country buys the same lines the global market does, in the same order. Volume sits in Powder at 54.5% of 2025 revenue; movement sits in Tablets & Capsules at 10.07% growth. Weighting toward Latin America means competing for 8% of 2025 global revenue, a base of USD 55.2 million moving to USD 113.1 million across the forecast period.

Mexico is sized at USD 16.6 million in 2025, rising to USD 33.9 million by 2034; 2.4% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 6% of global revenue puts 2025 at USD 41.4 million rising to USD 84.9 million in 2034. Among the five regions it ranks fifth by revenue in both years.

By 2034 the share stands at 6%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Powder leads here as it does globally, at 54.5% of 2025 revenue, and Tablets & Capsules again grows fastest at 10.07%. Middle East and Africa is reported axis by axis and country by country in the full study.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 14.5 million in 2025 and projected to reach USD 29.7 million by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Regional revenue of USD 41.4 million in 2025 and USD 84.9 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Saudi Arabia follows the product type mix reported at global level: Powder is the largest line at 54.5% of 2025 revenue, moving to 50% by 2034, while Tablets & Capsules grows fastest at 10.07% and takes its share from 28.5% to 33%. With 35% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-product type revenue for Saudi Arabia appears on its own in the full report.

In Saudi Arabia, spirulina sold as a food or dietary supplement is regulated by the Saudi Food and Drug Authority, which requires the product to be registered in the national food product system before it can be placed on the market. The authority classifies dietary supplements separately from conventional foods and from herbal or traditional medicines, and a supplier must demonstrate that the formulation, contaminant levels, and permitted claims align with the authority's own technical requirements as well as the wider Gulf Cooperation Council standards that Saudi Arabia applies. Labelling must be presented in Arabic alongside any other language used, state the product's classification clearly, and avoid claims suggesting the product treats or prevents disease, since such claims would place it outside the supplement category entirely.

Saudi Arabia does not have a competitive structure of its own; position here is position on the product type axis reported above. Volume sits in Powder at 54.5% of 2025 revenue; movement sits in Tablets & Capsules at 10.07% growth. The commercial size of that position is USD 41.4 million in 2025 and USD 84.9 million by 2034, 6% of the global total in the base year.

Within Middle East and Africa, South Africa accounts for 25% of regional revenue and 1.5% of the global total, worth USD 10.4 million in 2025 and USD 21.2 million by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product Type, Application, End User, Distribution Channel, Cultivation Method, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.